REVIEW LEDGER
论文复核台
集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。
| 论文 | 元数据入排 | 图像/No. at risk 复核 | 依据 |
|---|---|---|---|
| A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer.PMID 39354670 · 2025-Feb-04 | needs_reviewThe record describes the protocol of a randomized phase III trial with a drug intervention in oncology, but the primary endpoint is stomatitis incidence, not a time-to-event efficacy endpoint (e.g., OS, PFS). Furthermore, the abstract presents aims and design, not formal trial results. | pending- | The record describes the protocol of a randomized phase III trial with a drug intervention in oncology, but the primary endpoint is stomatitis incidence, not a time-to-event efficacy endpoint (e.g., OS, PFS). Furthermore, the abstract presents aims and design, not formal trial results. |
| Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01).PMID 39326505 · 2025-Feb-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up.PMID 39508462 · 2025-Feb-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.PMID 39699905 · 2025-Feb-01 | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.PMID 39874977 · 2025-Feb-01 | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.PMID 39261236 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.PMID 39365958 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.PMID 39374473 · 2025-Feb | needs_reviewMetadata establishes all primary eligibility criteria: oncology (NSCLC), human, randomized (multicenter RCT), phase III (explicitly stated), time-to-event primary endpoint (PFS) and secondary endpoint (OS) with HRs. The intervention includes a drug (EGFR-TKI). The report is the original results of a definitive trial. The deterministic review flagged 'drug_intervention_unclear', but the abstract explicitly describes EGFR-TKIs as the standard-of-care comparator in both arms, making it a drug-containing intervention. | pending- | Metadata establishes all primary eligibility criteria: oncology (NSCLC), human, randomized (multicenter RCT), phase III (explicitly stated), time-to-event primary endpoint (PFS) and secondary endpoint (OS) with HRs. The intervention includes a drug (EGFR-TKI). The report is the original results of a definitive trial. The deterministic review flagged 'drug_intervention_unclear', but the abstract explicitly describes EGFR-TKIs as the standard-of-care comparator in both arms, making it a drug-containing intervention. |
| A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.PMID 39442617 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy.PMID 39477187 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC.PMID 39521434 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.PMID 39532203 · 2025-Feb | needs_reviewThe trial is a Phase III randomized trial in human oncology with a drug intervention (capecitabine), but the primary efficacy endpoint is organ preservation rate (a binary outcome), not a standard time-to-event endpoint (OS, PFS, DFS, etc.). While local regrowth is a time-to-event outcome, it is not presented as a primary or key secondary endpoint with Kaplan-Meier analysis or hazard ratios in the abstract. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort focused on time-to-event efficacy endpoints. | pending- | The trial is a Phase III randomized trial in human oncology with a drug intervention (capecitabine), but the primary efficacy endpoint is organ preservation rate (a binary outcome), not a standard time-to-event endpoint (OS, PFS, DFS, etc.). While local regrowth is a time-to-event outcome, it is not presented as a primary or key secondary endpoint with Kaplan-Meier analysis or hazard ratios in the abstract. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort focused on time-to-event efficacy endpoints. |
| Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.PMID 39581197 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.PMID 39602678 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.PMID 39642775 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity.PMID 39825571 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.PMID 39854806 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial.PMID 39884222 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.PMID 39914418 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.PMID 39914419 · 2025-Feb | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.PMID 39842010 · 2025-Jan-23 | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.PMID 39798578 · 2025-Jan-18 | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.PMID 39798579 · 2025-Jan-18 | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.PMID 39813643 · 2025-Jan-16 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.PMID 39800716 · 2025-Jan-13 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.PMID 39389055 · 2025-Jan-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.PMID 39316653 · 2025-Jan-09 | needs_reviewThe record is a secondary analysis of two Phase III RCTs with a time-to-event endpoint (EFS). However, the abstract does not establish a drug-containing intervention; it focuses on risk stratification and outcomes of therapy protocols. Without explicit drug vs. non-drug (or standard-of-care) randomized comparison, the drug_intervention criterion cannot be met. | pending- | The record is a secondary analysis of two Phase III RCTs with a time-to-event endpoint (EFS). However, the abstract does not establish a drug-containing intervention; it focuses on risk stratification and outcomes of therapy protocols. Without explicit drug vs. non-drug (or standard-of-care) randomized comparison, the drug_intervention criterion cannot be met. |
| Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer.PMID 39074566 · 2025-Jan-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinoma.PMID 39222012 · 2025-Jan-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.PMID 39243945 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.PMID 39369790 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Prognostic Impact of Thoracic Duct Resection in Patients Who Underwent Transthoracic Esophagectomy Following Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: Exploratory Analysis of JCOG1109.PMID 39373925 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.PMID 39393777 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.PMID 39522825 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).PMID 39531903 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.PMID 39642900 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.PMID 39657575 · 2025-Jan | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.PMID 39700681 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients.PMID 39754976 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.PMID 39756844 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.PMID 39854658 · 2025-Jan | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review已识别 KM 曲线,但未在图像中识别到 No. at risk 表,需人工复核正文或补充材料。 | 已识别 KM 曲线,但未在图像中识别到 No. at risk 表,需人工复核正文或补充材料。 |
| Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy.PMID 40700835 · 2025 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.PMID 40795416 · 2025 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.PMID 39970442 · 2025 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.PMID 40625746 · 2025 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors.PMID 41194933 · 2025 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.PMID 39715755 · 2024-Dec-24 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.PMID 39292975 · 2024-Dec-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.PMID 39690158 · 2024-Dec-18 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/GEJ cancer.PMID 39093841 · 2024-Dec-15 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |